Related Experiment Video

Updated: Jul 25, 2026

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

Pimecrolimus for the Treatment of Atopic Dermatitis in Infants: An Asian Perspective

Chia-Yu Chu1, Tsung-Chieh Yao2, I-Hsin Shih3

  • 1Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.

Dermatology and Therapy
|February 3, 2023
PubMed

Insights

Pimecrolimus is recommended for infants aged 3 months to 2 years with atopic dermatitis in Asia. This topical calcineurin inhibitor offers a safe alternative to topical corticosteroids for managing this common pediatric skin condition.

Area of Science:

  • Dermatology
  • Pediatrics
  • Immunology

Background:

  • Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition in children, with rising incidence in the Asia-Pacific region.
  • Genetic, environmental, and cultural factors influence AD presentation and prevalence across different populations.
  • Early intervention is crucial to prevent the atopic march, a progression to conditions like asthma and allergic rhinitis.

Purpose of the Study:

  • To evaluate the safety and efficacy of pimecrolimus for treating atopic dermatitis in pediatric patients.
  • To address concerns regarding pimecrolimus use in infants within Asian countries.
  • To provide expert recommendations on pimecrolimus application in young children.

Main Methods:

  • Review of clinical trial data on pimecrolimus efficacy and safety.
  • Comparison of pimecrolimus with topical corticosteroids (TCS) and tacrolimus.
  • Expert panel assessment of evidence for pimecrolimus use in infants.

Main Results:

  • Pimecrolimus (1%) is a topical calcineurin inhibitor (TCI) effective for mild to moderate AD.
  • Pimecrolimus demonstrates a comparable safety profile to TCS with fewer adverse events and less burning sensation than tacrolimus.
  • Despite established efficacy, regulatory restrictions on pimecrolimus in infants persist in many Asian nations.

Conclusions:

  • Expert panel recommends pimecrolimus for infants aged 3 months to 2 years in the Asian population.
  • Pimecrolimus is a viable and safe alternative to long-term topical corticosteroid use.
  • Evidence supports the use of pimecrolimus to manage pediatric atopic dermatitis, mitigating risks associated with other treatments.

Keywords:
Asian populationAtopic dermatitisInfantsPimecrolimusTopical calcineurin inhibitor

More Related Videos

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

Murine Model of Epicutaneously-Induced Immunomodulation09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

Related Concept Videos

Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...